Prominent investors criticize Lundbeck's share structure split
Pharmaceutical firm Lundbeck’s recently proposed split share structure has not been well received by some big investors.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
Last week, Lundbeck announced a new share structure dividing shares into two categories, which would allow the company to hunt for external financing without the Lundbeck Foundation, which is the majority shareholder, having to relinquish any power.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck preps for war against generic drugmakers in US
For subscribers
